GlassScriptPhysician profile
Richard A Limbert
NPI 1518222082
$12,156.88
in general payments reported to CMS, 2019-2025
31 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,923 · 2020: $1,537 · 2021: $1,605 · 2022: $1,737 · 2023: $2,140 · 2024: $1,622 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,160 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,159.50 |
| Education | $195.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,693.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,269.46 | 2019-2025 | |
| Janssen Biotech, INC. | $1,115.91 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $1,033.95 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $849.84 | 2019-2024 | Dupixent, Libtayo |
| Ucb, INC. | $784.24 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $634.23 | 2019-2025 | Taltz, Zepbound, Ebglyss |
| Sun Pharmaceutical Industries INC. | $582.97 | 2019-2025 | Odomzo, Blu-U |
| Leo Pharma INC. | $510.15 | 2019-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $438.39 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $421.80 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $339.09 | 2019-2025 | |
| Galderma Laboratories, L.P. | $293.53 | 2019-2025 | Nemluvio |
| Pfizer INC. | $258.57 | 2022-2024 | |
| Aclaris Therapeutics, INC. | $146.83 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $107.53 | 2019 | |
| Botanix Sb INC | $89.75 | 2025 | Sofdra |
| Incyte Corporation | $77.78 | 2022-2024 | Opzelura |
| Dusa Pharmaceuticals, INC. | $76.21 | 2019 | |
| Almirall LLC | $66.91 | 2019-2025 | Klisyri |
| Merck Sharp & Dohme LLC | $61.82 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $57.62 | 2025 | Zoryve |
| Smith+Nephew, INC. | $40.99 | 2020-2023 | Grafix Pl |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.52 | 2019-2020 | |
| Organon LLC | $38.20 | 2025 | Vtama, Hadlima |
| Convatec INC. | $34.93 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.03 | 2022 | |
| Dermira, INC. | $21.75 | 2019 | |
| Biofrontera INC. | $19.47 | 2019 | |
| Mayne Pharma Commercial LLC | $15.59 | 2019 | |
| Genentech USA, INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Limbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.